![[Valid Atom 1.0]](images/valid-atom.png "Valid Atom 1.0")
This is a valid Atom 1.0 feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom"> <id>https://ijpcr.net/ijpcr/issue/feed</id> <title>International Journal of Pharmacology and Clinical Research (IJPCR)</title> <updated>2024-10-18T17:14:35+00:00</updated> <author> <name>Dr.N.Sriram</name> <email>ijpcreditor@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr" /> <link rel="self" type="application/atom+xml" href="https://ijpcr.net/ijpcr/feed/atom" /> <generator uri="http://pkp.sfu.ca/ojs/" version="3.1.2.4">Open Journal Systems</generator> <subtitle type="html"><p><strong><em>International Journal of Pharmacology and Clinical Research (IJPCR) </em></strong>is a peer-reviewed, quarterly official international journal allowing access to abstracts<strong>&nbsp;</strong>and<strong>&nbsp;</strong>full-text. The journal is devoted to the promotion of pharmaceutical sciences and related disciplines (Pharmacology, Biopharmaceutics, Pharmacokinetics, Pharmaceutical Medicinal Chemistry, Computational Chemistry &amp; Molecular Drug Design, Pharmacognosy &amp; Phytochemistry, Pharmaceutical Analysis, Pharmacy Practice, Clinical &amp; Hospital Pharmacy, Cell Biology, Genomics &amp; Proteomics, Pharmacogenomics, Bioinformatics including biotechnology, cell &amp; molecular biology, Pharmaceutical biotechnology/microbiology, medical and other life sciences).</p> <p><strong>ISSN</strong>&nbsp;-&nbsp;<strong><em>International Journal of Pharmacology and Clinical Research (IJPCR)</em></strong></p> <p><strong>Online</strong>:<strong>&nbsp;</strong>2521-2206</p> <p><strong><em>International Journal of Pharmacology and Clinical Research </em></strong>seeks to foster multidisciplinary research and collaboration among scientists, pharmaceutical industries and healthcare sector as well as provide an international forum for the communication and evaluation of data, methods and opinions in pharmaceutical sciences and related disciplines. Although primarily devoted to original research papers, the journal particularly welcomes reviews on current topics of special interest and relevance. All manuscripts will be subjected to rapid peer review. Those of high quality (not previously published and not already under consideration for publication) will be published.</p></subtitle> <entry> <id>https://ijpcr.net/ijpcr/article/view/613</id> <title>Rp-Hplc Method Development And Validation For The Determination of Vismodegib In Pharmaceutical Dosage Form </title> <updated>2024-10-16T17:12:41+00:00</updated> <author> <name>Chikkela Sai Meghana</name> <email>saimeghana415@gmail.com</email> </author> <author> <name>Gorantla Nagamallika</name> <email>saimeghana415@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/613" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/613"><p>A Simple, sensitive, specific and precise RP-HPLC method for the pharmaceutical dose estimation of Vismodegib. Chromatogram was run through AscentisC18 150 x 4.6 mm, 5m. Mobile phase containing 0.1%NA<sub>2</sub>HPO<sub>4</sub>: Acetonitrile taken in the ratio 60:40was pumped through column at a flow rate of 1.0ml/min. Buffer used in this method was Sodium Hydrogen Phosphate (4.0ph) buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 260.0nm. Retention time of Vismodegib was found to be 2.585 min. %RSD of the Vismodegib were and found to be 0.9. %RSD of Method precision of Vismodegib was found to be 0.5.%Recovery was obtained as 99.76% for Vismodegib. LOD, LOQ values obtained from regression equation of Vismodegib were 0.57, 1.72. Regression equation of Vismodegib isy = 37710x + 19681. Retention times were decreased, and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.</p></summary> <published>2024-10-16T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/614</id> <title>Formulation And Evaluation Of Mouth Dissloving Flims Of Glycopyrrolate</title> <updated>2024-10-16T17:20:30+00:00</updated> <author> <name>S. Priyanka</name> <email>sanugalipriyanka72306@gmail.com</email> </author> <author> <name>Shiva Srikrishna</name> <email>sanugalipriyanka72306@gmail.com</email> </author> <author> <name>K. Nagasree</name> <email>sanugalipriyanka72306@gmail.com</email> </author> <author> <name>K. Shravankumar</name> <email>sanugalipriyanka72306@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/614" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/614"><p>Glycopyrrolate is an opioid pain medication used to treat moderate to moderately severe pain. When taken by mouth in an immediate-release formulation, the onset of pain relief usually begins within an hour. Present work aimed at preparing quick onset of action which is beneficial in hypertension, aiding in the enhancement of bioavailabity and is very convenient for administration without the problem of swallowing and using water. The film was prepared by using polymers such as Sodium alginate, Pectin and HPMC by a solvent casting method.&nbsp; They were evaluated for physical characteristics such as Thickness, Weight Variation, Disintegration time, Drug content, Tensile strength, % Elongation, Folding Endurance and <em>In vitro</em> Dissolution Studies give satisfactory results. The <em>in vitro</em> dissolution time of the optimized batch G7 was found to be 99.54%.&nbsp; The optimized batch <em>in vitro</em> disintegration time was found to 15 sec. &nbsp;</p></summary> <published>2024-10-16T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/615</id> <title>A Study On Assessment Of Diabetic Foot Ulcers In A Tertiary Rohini Hospital</title> <updated>2024-10-16T17:30:43+00:00</updated> <author> <name>K. Veera Brahmananda Reddy</name> <email>kunreddy125@gmail.com</email> </author> <author> <name>M. Vidhya</name> <email>kunreddy125@gmail.com</email> </author> <author> <name>D. Swathi</name> <email>kunreddy125@gmail.com</email> </author> <author> <name>K. Shravankumar</name> <email>kunreddy125@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/615" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/615"><p><strong>Background:</strong> Diabetic foot ulcer is one of the most significant and devastating complications of diabetes, and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes. The global diabetic foot ulcer Prevalence was 6.3% which was higher in males than in females and higher in t2dm than in t1dm.</p> <p>Aims And Objectives: To determine the prevalence, drug prescribing patterns, severity of diabetic foot ulcer and to assess the anxiety and depression using HADS scale in type 2 diabetes patients.</p> <p><strong>Materials And Methodology:</strong> A Prospective observational study with a sample size of 130 patients in a period of 6 months was conducted as per inclusion and exclusion criteria. Clinical data is collected from patients who are diagnosed with diabetic foot ulcer and received anti-diabetic medications.</p> <p><strong>Results:</strong> According to our study males 76.0% ( 99)were more prevalant than females 24.0% (31). Majority of patient were on 127(97.7%)Insulin treatment and 19 were on oral hypoglycaemic treatment and 115 (88.5%)Beta lactamase inhibitors, 113 (86.9%)cephalosporins and 73(56.2%)macrolides were highly prescribed . Majority of patients were in grade - 3 41.5% (54)&nbsp; severity of DFU . Anxiety 28 (21.5%)was majorly observed when compared to the Depression 14 (10.8%) according to HADS scale .</p> <p><strong>Conclusion:</strong> Foot ulcers in patients with diabetes is common, and frequently leads to lower limb amputation unless a prompt, rational, multidisciplinary approach to therapy is taken. The health care providers are recommended to enhance preventive measures in the reduction of foot ulcer through promoting foot self-care practice, giving special emphasis during follow-up of patients who came from rural areas, educating the patient to reduce overweight gain, and managing the neuropathy thoroughly in order to decrease the occurrence of diabetic foot ulcer.</p></summary> <published>2024-10-16T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/616</id> <title>Impact Of Patient Information Leaflet And Management Of Levothyroxine Among Pregnant Women With Hypothyroidism</title> <updated>2024-10-16T17:42:09+00:00</updated> <author> <name>B. Mahender</name> <email>bashettimahender@gmail.com</email> </author> <author> <name>A. Rajendraprasad</name> <email>bashettimahender@gmail.com</email> </author> <author> <name>D. Swathi</name> <email>bashettimahender@gmail.com</email> </author> <author> <name>K. Shravankumar</name> <email>bashettimahender@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/616" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/616"><p>&nbsp;Hypothyroidism an endocrine disorder is an underactive thyroid gland, which does not make enough thyroid hormone. Hypothyroidism during pregnancy can have irreversible effects on the fetus. Treatment of hypothyroidism during pregnancy is given with levothyroxine based on the assessment of thyroid functioning. The present study was aimed to counsel patients using patient information leaflet and management of levothyroxine in a tertiary care hospital. The main objectives are to develop a PIL, identify the application and its usefulness, and to understand the drug utilization evaluation in hypothyroid pregnant patients. A prospective observational study was carried out including 98 pregnant women with hypothyroidism during august 2019 to January 2020. A total of 98 patients were enrolled in the study, the percentage distribution of subjects age showed that the age group of 18-25 were predominant. Among them, 48 were in the first trimester. All the patients were counseled using PIL and appropriate feedback was collected. Management of levothyroxine was carried out from the level of TSH and dose of levothyroxine collected during follow up. Hence it can be concluded that patient information leaflets can show a great impact on patients by improving their condition and thus, a reduction in dose can be achieved.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></summary> <published>2024-10-16T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/617</id> <title>Evaluation Of Anti-Depressant Effect Of Euphorbia Cyanthophora Leaves In Reserpine Induced Cns Depression In Rats</title> <updated>2024-10-18T16:53:17+00:00</updated> <author> <name>K. Akashraj</name> <email>akash890vkl@gmail.com</email> </author> <author> <name>G. Muthukumaran</name> <email>akash890vkl@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/617" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/617"><p>The Aim is to perform the anti-depressant effect of Ethanolic extract of <em>euphorbia cyanthopora </em>leaves. Initially the plant leaves are collected and subjected for drying. Extraction is done with ethanol for a period of time and was used to perform preliminary phytochemical tests are to be done with the extraction and then the extract was used for the testing the in-vitro anti-oxidant studies and followed by the behavourial studies are done for the estimation of the drug. Then the in-vivo pharmacological studies are done for the estimation then the invitro studies done by sacrifising the animal then the bio chemical studies are to be done and finally the statistical analysis done for the identification of the activity done by the drug.</p></summary> <published>2024-10-18T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/618</id> <title>Preparation And In Vitro Evaluation Of Glimepiride Sustained Release Matrix Tablets</title> <updated>2024-10-18T17:07:25+00:00</updated> <author> <name>Rafqua Zeb</name> <email>rafquazeb786@gmail.com</email> </author> <author> <name>Ramakrishna Mungi </name> <email>rafquazeb786@gmail.com</email> </author> <author> <name>K. Balaji </name> <email>rafquazeb786@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/618" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/618"><p>The aim of the present study was to develop sustained release formulation of Glimepiride to maintain constant therapeutic levels of the drug for over 12 hrs. HPMC-K 100 M, Sodium Carboxy Methyl Cellulose, Grewia gum, Almond gum were employed as polymers. All the formulations were passed various physicochemical evaluation parameters and they were found to be within limits. Whereas from the dissolution studies it was evident that the formulation (F9) showed better and desired drug release pattern i.e., 99.9% in 12 hours. It contains the HPMC-K 100 M 1:1 as sustained release material. It followed Zero order release kinetics mechanism.</p></summary> <published>2024-10-18T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/619</id> <title>Evaluation Of Anti-Ulcer Activity Of Canthium Dicoccum Extract In Experimental Animal Model</title> <updated>2024-10-18T17:14:35+00:00</updated> <author> <name>Geeta Vani</name> <email>pittalaswathi@gmail.com</email> </author> <author> <name>Pittala Swathi</name> <email>pittalaswathi@gmail.com</email> </author> <author> <name>D. Venkata Ramana</name> <email>pittalaswathi@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/619" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/619"><p>The cause of ulceration in patients is mainly due to hypersecretion of gastric juice and also due to hypersecretion of pepsin. In traditional system of medicine a number of herbal preparations have been used for the treatment of peptic ulcers. There are various medicinal plants has been used for the treatment of gastrointestinal disorders. In view of this, in present study we have to evaluate the anti-ulcer activity of <em>Canthium Dicoccum</em>. Study was carried out, by using three methods i.e.,alcohol, paracetamol and stress induced ulcers in rats pretreated with the doses of 250 mg/kg AQCR and ALCR, 10mg/kg Omeoprazole and 50 mg/kg Ranitidine. To evaluate the antiulcer activity of aqueous and alcoholic extracts of <em>Canthium Dicoccum </em>leaves (AQCR and ALCR) at 250 doses using different experimentally induced gastric ulcer models in rats. Gastric ulcers were induced in rats by 80% alcohol, paracetamol and forced immersion stress induced methods. In alcohol induced ulcer model, paracetamol induced ulcer model and stress induced model the ulcer index was determined. Where as in stress induced ulcers stress plays an important role in ulcerogenesis. &nbsp;In alcohol-induced ulcers, AQCR and ALCR were effective in reducing lesion index and increasing the gastric mucus content. It was also effective in decreasing ulcer index in paracetamol-induced ulcers. All the results obtained with <em>Canthium Dicoccum </em>were dose dependent. <strong>&nbsp;</strong>The results suggest that AQCR and ALCR possesses significant and dose dependent antiulcer activity. The antiulcer activity of AQCR and ALCR can be attributed to its cytoprotective and antisecretory action.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></summary> <published>2024-10-18T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> </feed> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid Atom 1.0" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
